However, it has been reported that in 50–80% of patients PrCa was not detected when performing prostate biopsy based only on high serum PSA levels [18], suggesting the need for a systematic evaluation of not only tumor markers but also imaging and pathological findings on biopsy specimens from metastatic lesions. This evidence concerns the gene KLK3 and pure red-cell aplasia.